“The fulcrum of the focus has shifted to the domestic market and I think one concern is possibly valuations and that is something that the market would have to deal with. In general, when the cost of capital goes up, it is the highly valued expensive sectors that tend to suffer most. Pharma is one sector that has suffered on that count, consumer staples could be another one.”
